Possible dopaminergic pathway from substantia nigra to putamen.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001479:Basal Ganglia / Q000502:physiology*; D002415:Cats; D003864:Depression, Chemical; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D004558:Electric Stimulation; D005071:Evoked Potentials; D005260:Female; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009413:Nerve Fibers, Myelinated / Q000502:physiology; D009431:Neural Conduction; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D010648:Phenylacetates / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013268:Stimulation, Chemical; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission; D014439:Tyramine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D008996:Monoamine Oxidase Inhibitors; D010648:Phenylacetates; D012701:Serotonin; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine; D014439:Tyramine